All posts by imreal

Vern Coates Joins Independent Broker Dealer Recruiter Henschen & Associates as Senior Vice President of Business Development


photo of Vern Coates, Henschen & Associates

Vern Coates, SVP Business Development Henschen & Associates

“There are pivotal moments that can have a lasting impact on an advisor’s practice. Changing broker dealers is certainly one of those times and having a partner like Henschen & Associates can minimize the challenges and enhance the opportunities.”-Vern Coates

Henschen & Associates announces the appointment of Vern Coates to Senior Vice President of Business Development. Coates brings 12 years of financial services industry experience, where his primary focus has been to help financial advisors find the right independent broker dealer for their practice.

Before joining Henschen & Associates, Coates was at Berthel Fisher & Company Financial Services Inc., an industry-leading financial advisory firm headquartered in Cedar Rapids, Iowa. At Berthel Fisher, Coates held two positions for two separate broker dealers under the same parent company.

Most recently, he was Regional Director Business Development, where served as a trusted resource for over 200 financial advisors looking to increase revenue, complete succession plans, add new advisors, and have a consistent sounding board for achieving practice goals. During his tenure, he attracted high quality advisors to Berthel Fisher’s expanding mid-size independent financial services firms, and partnered with existing practices to help increase average regional revenue by more than 10% annually.

Prior to his business development role, Coates served as Recruiting Manager, where he led an experienced team of recruiters with a track record for identifying top talent in the independent broker dealer space. Over a 10-year span, Coates was ranked the #1 recruiter by revenue for 10 years covering 2 different broker dealers.

Coates has held Series 7, 24 and 66 securities licenses along with life and health insurance registrations. In addition to his Law Enforcement degree, Vern has a Business Administration degree from Coe College in Cedar Rapids, Iowa.

According to Henschen & Associates Founder Jon Henschen, “Vern is the perfect fit for Henschen & Associates. He brings an impressive record of recruiting and placing top talent in the independent broker dealer space. He and I both place heavy emphasis on building long-term relationships with the advisors we work with, so I am energized to have Vern onboard to enhance the services and opportunities we can provide to them.

On the new relationship, Coates adds, “Jon Henschen is widely respected as a thought leader in our industry and has built Henschen & Associates into a trusted partner for financial advisors. His in-depth knowledge and insight into the independent broker dealer channel is virtually unmatched, as is his attention to due diligence and the details that matter most to advisors, and I’m excited to add my own deep experience and dedication to financial advisors working alongside Jon.”

Coates continued, “There are pivotal moments that can have a lasting impact on an advisor’s practice. Changing broker dealers is certainly one of those times and having a partner like Henschen & Associates can minimize the challenges and enhance the opportunities. We want our advisors to reap the rewards of our combined expertise, 30 years of industry experience, and 60 unique broker dealer value propositions. There is no substitute for having an unbiased ally to provide unparalleled consultation during this critical time.”

Headquartered in Marine on St. Croix, Minnesota, Jon Henschen founded Henschen & Associates in 2001 with the goal of focusing on the independent broker dealer channel and working with a broad array of firms that met different needs. Today, Henschen & Associates contracts with more than 60 independent broker dealers, matching representatives with the broker dealer that best meets their profile and needs.

To learn more about Henschen & Associates, visit: http://www.henschenassoc.com

Share article on social media or email:

National Certification Board for Aging and Alzheimer Care (NCBACtm) Announces Availability of Version 3 of CRTS(tm) Certified Relocation Transition Specialist Training


News Image

Industry leading certification for more than a decade

The aging US population brings with it a host of new challenges. In larger numbers than ever before, Senior Citizens face the need to modify or change their living arrangements. Most often this involves downsizing to a smaller home, condo, or assisted living facility. For a few, it may involve modifying their existing residence.

Change is difficult for most people. Studies show that our concept of “home” is hardwired in our brains. It’s at the core of who we are. Giving up possessions can be very unsettling for Seniors as well as their families. In many cases, family homes are intrinsically tied to our identities.

NCBAC’s CRTS Certification Program features an 18 module course which provides comprehensive information needed to successfully organize and manage Senior moves from beginning to setting up the new home.

The voice-over narration has just been added, as well as updated statistics and detailed on-line illustration. The information is easy to follow and is designed to provide Transition Specialists with the plans and techniques necessary to reduce stress and manage moves effectively.

CRTS emphasizes a team approach for project management. It covers topics such as working with families, communication techniques, dealing with physical limitations, downsizing decisions for personal possessions, finding appropriate housing alternatives, moving issues and resettling into a new home.

Transition Specialists come from many other professions including professional organizers, caregivers and housing personnel, real estate agents, estate sales specialists, attorneys, movers and medical personnel.

This program meets national certification standards and is the premier national certification of its type.

For more information, including special rates: http://www.crtscertification.com

Share article on social media or email:

Author W. Dwightel Weathers’s new book “Jehovah, My God and Father, Is Real” is an autobiographical reflection on the relationships he has enjoyed throughout his life


News Image

W. Dwightel Weathers, a Mississippi-born writer and poet who has lived with his family in Miami, Florida, since 1960, has completed his new book “Jehovah, My God and Father, Is Real”: a candid autobiography of his marriages, romances, and spiritual journey to date.

The author writes, “’Jehovah, My God and Father, Is Real’ is a love story directed by Jehovah in unbelievable fashion. It shows that God is alive and active in the lives and affairs of people today, just as he was in the days of the people in the Old and New Testament. When we love and obey him, he blesses us beyond our comprehension.”

Published by New York City-based Page Publishing, W. Dwightel Weathers’s inspiring book is a deeply personal memoir paying homage to the role of his faith in every aspect of his life.

Readers who wish to experience this engaging work can purchase “Jehovah, My God and Father, Is Real” at bookstores everywhere, or online at the Apple iTunes store, Amazon, Google Play, or Barnes and Noble.

For additional information or media inquiries, contact Page Publishing at 866-315-2708.

About Page Publishing:

Page Publishing is a traditional New York-based, full-service publishing house that handles all the intricacies involved in publishing its authors’ books, including distribution in the world’s largest retail outlets and royalty generation. Page Publishing knows that authors need to be free to create – not overwhelmed with logistics like eBook conversion, establishing wholesale accounts, insurance, shipping, taxes, and the like. Its roster of accomplished authors and publishing professionals allows writers to leave behind these complex and time-consuming issues to focus on their passion: writing and creating. Learn more at http://www.pagepublishing.com.

Share article on social media or email:

Forecast International Sees Cyberspace A Growing Focus of U.S. Defense Electronics Market


News Image

The defense electronics market in the United States continues to focus on enhancing, modernizing, and upgrading existing systems while at the same time developing new technologies.

Computer and information technology advancements have propelled C5ISR to the top of the U.S.’s defense electronics market. Forecast International projects that this market will be worth at least $171.2 billion from 2020-2029.

“The defense electronics market in the United States continues to focus on enhancing, modernizing, and upgrading existing systems while at the same time developing new technologies,” said Richard Sterk, Senior Analyst and editor of Forecast International’s yearly analysis ‘The Market for U.S. Defense Electronics.’ Sterk further said that, “Integrating multimission systems and applications through networking into real-time operations remains a priority of the C5ISR – command, control, communications, computers, combat systems, and intelligence, surveillance and reconnaissance – industry. Examples of technology that achieve this end include network battle command and logistics systems, networked precision missiles and gun-launched munitions, improved intelligence sensors, and active and passive protection systems. These technologies, in turn, have created additional submarkets such as cyber warfare, cybersecurity, and surveillance/reconnaissance radars.”

Forecast International’s projections are the result of a review and analysis of 564 leading defense electronics programs. The top defense electronics companies in the U.S. market continue to draw from the upper echelons of corporate America. The analysis projects that the top five U.S. defense electronics companies over the next 10 years in terms of market value will be Lockheed Martin, Northrop Grumman, Raytheon, L3Harris, and BAE Systems.

“Meeting the challenges of the cyber warfare threat will lead to lucrative opportunities for the development of both offensive and defensive systems,” said Sterk. “Due to the extensive use of networks and software, the U.S. faces an evolving array of cyber-based threats. These threats can be intentional or unintentional. Unintentional threats can result from software upgrades or defective equipment that inadvertently disrupt systems. Intentional threats are targeted attacks, originating from a number of sources.”

The following systems, products, and programs are projected to lead the market in sales over the 10-year forecast period: the APG-81 AESA radar for F-35 aircraft; the ICNIA (Integrated Communications, Navigation, Identification, Avionics) system that will integrate aircraft avionics for the F-22 and the F-35; the APG-68 pulse-Doppler fire control radar for the F-16; the AAQ-33 Sniper Advanced Targeting Pod; the ALQ-210 situational awareness and threat warning system; the SPY-6 Air and Missile Defense Radar (AMDR) to be installed aboard aircraft carriers and destroyers; the AQS-20 minehunting sonar and AQS-22 ALFS (Airborne Low Frequency Sonar) naval systems; the Navy Multi-band Terminal C4I system; the PRC-150 and PRC-152 combat radios; and the VAS-5 Driver’s Vision Enhancer for land vehicles.

About Forecast International

Forecast International, Inc. is a leading provider of Market Intelligence and Consulting in the areas of aerospace, defense, power systems and military electronics. Based in Newtown, Conn., USA, the company specializes in long-range industry forecasts and market assessments used by strategic planners, marketing professionals, military organizations, and governments worldwide. Forecast International also maintains a high posture of situational awareness and geopolitical analysis.

Share article on social media or email:

Hera BioLabs (“Hera”) and Demeetra Ag Bio (“Demeetra”) announce joint launch of Cas-CLOVER™ the “clean alternative to CRISPR/Cas9 for drug discovery and bioprocessing”


Cas-CLOVER – the best of both CRISPR/Cas9 and TALEN gene editing

“High fidelity editing is extremely important to us and our partners as off-targets can effect important characteristics…

Announcement Key Points:

Hera and Demeetra stem from the gene editing platforms company Transposagen (now a Hera BioLabs company) which is best known for its commercialization of the piggyBac® transposase

Cas-CLOVER differs from single-guided CRISPR and dual-guided CRISPR nickase systems as it is truly dimeric and demonstrates high fidelity with no detectable off-targets while maintaining robust editing efficiency

Issued patents cover these technologies enabling clear freedom-to-operate

Evaluation opportunities and services for Cas-CLOVER which can convert into full research and commercial licenses with very accessible terms are available

Demeetra is operating in the pharmaceutical/industrial bioprocessing space as well as agricultural biotechnology, while Hera is focused on products tools and services for research and drug discovery

Targeted nuclease gene editing is a powerful tool for accelerating and improving opportunities for successful drug and cell therapy development from target identification and candidate selection through the production of GMP biologics. And has been used successfully to engineer T-cell therapies. Technologies such as ZFNs, CRISPR/Cas9 and now Cas-CLOVER bind to the target DNA and generate insertions and deletions (“indels”) resulting in “knockout” mutations or targeted “knock-ins” when supplied with the appropriate guide RNA(s) and donor vector.

CRISPR/Cas9 was a breakthrough for gene editing since it offers a simple and cost-effective method for high efficiency modification of the desired target locus. CRISPR does have a known trade-off as the technology demonstrates high degrees of off target mutagenesis, modifying the genome at undesired locations, in addition to the gene of interest. Off-target mutagenesis also occurs with the dual guided CRISPR nickase system which has been characterized as not truly dimeric (1, 2). Furthermore, licensing restrictions or lack of clear commercial freedom to operate have limited CRISPR/Cas9 use commercially.

Unlike CRISPR/Cas9, which is a monomeric nuclease targeted by a single guide RNA, Cas-CLOVER is a dimeric nuclease system targeted by 2 guide RNAs and has no detectable off-target mutations (3).

The Cas-CLOVER dimeric system uses two guide RNAs targeting “half-site” sequences. The two half-sites are separated by a spacer region where genomic DNA is cleaved with the proprietary dimeric Clo51 nuclease. The stringency of the dimeric Clo51 nuclease gives it the specificity that has shown no off-target activity after millions of next generation sequencing (NGS) reads in human T-cells. Guide RNA design for any gene of interest is flexible, as the spacer region between the guides is ideally between 16-30 bases (4).

“High fidelity editing is extremely important to us and our partners as off-targets can effect important characteristics such as growth rate and cloning efficiency in bioprocessing systems” said Jack Crawford CEO of Demeetra. Demeetra and Hera recently collaborated to validate Cas-CLOVER in Chinese hamster ovary (CHO) cell lines for bioprocessing. “Cas-CLOVER is a perfect fit for us as we move into crop trait engineering where we want to minimize off-target risks and reduce timelines due to backcrossing which is required with traditional chemical mutagenesis” he added.

Hera’s SRG OncoRat® is another example of nuclease applications. The Sprague Dawley strain was engineered to contain a knockout in both the Rag2 and IL2rg genes resulting in a fully immunodeficient rat. Dozens of human tumor models have been validated in the OncoRat, including a prostate cancer model recently published in a top tier drug development journal (5).

“Cell and gene therapy research may especially benefit from Cas-CLOVER where off-target mutagenesis is unacceptable” added Mike Schlosser the CEO of Hera. Both proliferating and resting human T-cells have been successfully targeted by Cas-CLOVER to remove cell surface markers associated with graft versus host disease (GVHD) (4).

About Hera

Hera Biolabs, Inc., based in Lexington, KY is an innovative preclinical contract services, products and licensing company. Our mission is to use cutting-edge gene-editing technologies to accelerate preclinical research and drug and cell-based therapeutic discovery and development. Hera built the SRG platform, an immunocompromised double knockout Sprague-Dawley rat engineered for T-cell, B-cell, and NK cell deficiency. Our first established commercial model is the SRG OncoRat, a valuable complement or alternative to oncology studies in mice, and well suited for xenograft oncology studies given its excellent tumor take-rates, large tumor mass, and smooth transition from efficacy to safety. Hera sells the SRG OncoRat to researchers and has been conducting oncology/pharmacology studies for clients over the past 5 years. Using immunocompromised husbandry procedures, our experienced staff performs studies in our on-site state-of-the-art vivarium that features dual HEPA-filtered, disposable IVC rodent caging systems. We’re also continuing to use our proprietary Cas-CLOVER CRISPR system and piggyBac gene-editing technologies and know-how to expand our robust pipeline of models and services.

About Demeetra

Demeetra AgBio is “Engineering Traits for Life” by introducing gene editing technologies in the agriculture, industrial, pharmaceutical & animal health industries. We provide licenses for Cas-CLOVER (the clean CRISPR/Cas9 alternative) and piggyBac transposase or partner under joint development agreements for applications in the engineering of crops and agricultural animals, plant-based drug development and enhanced bioprocessing in human & animal health.

References

1.    Tsai et al. (2014) Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nature Biotechnology.

2.    Lee et al (2015) Site-specific integration in CHO cells mediated by CRISPR/Cas9 and homology-directed DNA repair pathway. Scientific Reports

3.    Li et al (2018) Cas-CLOVER™: A High-Fidelity Genome Editing System for Safe and Efficient Modification of Cells for Immunotherapy. Precision CRISPR Congress Poster.

4.    Wang et al. (2017) Genome Editing of Therapeutic CAR-T Cells Using A Novel Clo51-dCas9 (NextGEN™) CRISPR System. American Society for Cell & Gene Therapy Poster.

5.    Ponnusamy (2019) Orally -Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer. Clinical Cancer Research

Share article on social media or email:

Gilad&Gilad enters Taiwan with AgmaVet®, a Veterinary Product for Nerve Health


“There are over 1,000 active animal clinics in Taiwan and our professional sales team already covers 80% of them. Together with Gilad&Gilad expertise and reputation we are making AgmaVet® readily available to them.”

Gilad&Gilad a health science company based in Henderson, Nevada, with core competency in Neuroscience and the exclusive supplier of AgmaVet®, a unique veterinary dietary product for nerve health, has initiated a collaboration with Pet Enjoy Bio-Science Co., Ltd. for distribution in Taiwan.

According to Dr. Gad M. Gilad, CEO of Gilad&Gilad, “The Ministry of Health of Taiwan has issued a permit allowing our collaborating distributor, Pet Enjoy Bio-Science, to import and distribute AgmaVet in Taiwan. Pet Enjoy was founded by a team highly experienced in the veterinary market, very proficient in marketing and sales of superior pet healthcare products in Taiwan and East Asia.” Dr. Gilad adds that “this collaboration is part of Gilad&Gilad’s ongoing efforts to expand worldwide distribution and sales and allows us to establish presence in this thriving region.”

AgmaVet is a novel first-of-its-kind nutraceutical product affording what is surely the best available solution for maintaining healthy, pain-free nerve functions. “Using AgmaVet® to fortify the daily intake of the nutraceutical G-Agmatine® (Gilad&Gilad’s proprietary brand of agmatine) provides a safe and most effective solution for nerve resilience, normal sensory functions and nerve-dependent muscle strength, which are cardinal for good quality of life,” says Dr. Gilad.

“We are pleased to collaborate with Gilad&Gilad and to be the distributor of AgmaVet in Taiwan,” says Mr. PeterTu, General Manager of Pet Enjoy Bio-Science. “There is a growing demand in Taiwan’s veterinary pet market for good quality healthcare products and the companion animal health market is expected to grow considerably in the coming years,” he adds. “There are over 1,000 active animal clinics in Taiwan and our professional sales team already covers 80% of them. Together with Gilad&Gilad expertise and reputation we are making AgmaVet® readily available to them.”

According to export.gov (11/8/2019), the online portal of the International Trade Administration, US Department of Commerce, Taiwan’s pet food (dog and cat food) market rallied on import demand, growing by 11 percent to nearly $180 million, more than doubling over the past decade.

About Gilad&Gilad LLC

Gilad&Gilad is a health science company with core competency in Neuroscience. The company has developed the exclusive Agmaceuticals(TM) line of products based on the breakthrough discovery of the neuroprotective properties agmatine. AgmaVet® is the first-of-its-kind nutraceutical for animals containing G-Agmatine® (the best brand of agmatine), with superior effectiveness for healthy nerve functions. – For further information, visit https://ForNerveHealth.com.

About Pet Enjoy Bio-Science

Pet Enjoy Bio-Science is a company based in Taiwan with expertise in marketing, distribution and sales of best solutions to unmet needs of the veterinary clinical practice and of animal healthcare by pet owners. Its mission is to become the best animal healthcare distribution partner in the ASIAN market. – For further information, visit http://www.petenjoy-bio.com.

Share article on social media or email:

Line Ally Baluwesi Mungurumia Chetesa Rossetti’s newly released “Adventure of Genet and Pangolin” shares an enjoyable tale of friendship between two forest animals


News Image

“Adventure of Genet and Pangolin”: a well-conceived children’s book about a genet and a pangolin’s unexpected friendship. “Adventure of Genet and Pangolin” is the creation of published author Line Ally Baluwesi Mungurumia Chetesa Rossetti, a writer, inventor, fashion designer, artist, entrepreneur, businesswomen, and a loving mother.

Rossetti shares, “The story is a perfect story for kids and family, a story anyone can relate to whether children or grown-ups.

“We all are going through life’s daily adventures. It is full of entertainment. It is witty, educational, and full of adventure. It is filled with inspiring messages that will inspire not just kids but the entire family:

“To see things and to live life out of sometimes what we are accustomed.

“In a sense, to enjoy life, to go with whatever the day brings us, whether it is difficult or a joyful, happy day.

“Especially in difficult days when someone is being extremely challenged with problems of the day and, in the midst of it, finding the solution not just for your problems, but how to help others overcome their problems

“In many cases we are all going through a pattern to try to help ourselves in the midst of trouble or difficulties, trying to figure out how to solve our problems or difficulties or whatever it might be in a sense without realizing that we are trying to do or to figure out something.

“Sometimes we do not have control over or things are out of our hands. They are in the hands of God always. He is the only one who has control over all things.

“That’s why God always reminds us in all things to pray and to seek His guidance through all things and no matter what sin not.

“After all, God says, in Hebrews 13:5, ‘I will never leave thee, nor forsake thee’ and in Matthew 28:20, ‘I am with you always, even unto the end of the world.’ Amen.”

Published by Christian Faith Publishing, Line Ally Baluwesi Mungurumia Chetesa Rossetti’s new book inspires readers to be compassionate toward others and seek the goodness within, regardless of appearances.

Follow the spirited adventure of a genet as he deals with inconveniences and is rewarded with a kind-hearted pangolin friend in the end.

View the synopsis of “Adventure of Genet and Pangolin” on YouTube.

Consumers can purchase “Adventure of Genet and Pangolin” at traditional brick-and-mortar bookstores or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Adventure of Genet and Pangolin,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

New study identifies trigger that turns dormant cancer stem cells into active ones


News Image

A new study released today in STEM CELLS identifies, for the first time, two morphologically and functionally different types of cancer stem cells found in cervical cancer. Of the two types, one exhibits an overexpression of cPLA2α, a key enzyme that triggers the transformation of dormant cancer stem cells into active ones, resulting in cervical cancer metastasis and recurrence. The information in this study could lead to new targets for treatments to halt tumor recurrence and metastatic spread. Also, it might accelerate the development of combination therapies.

The current standard of treatments for cervical cancer – the second leading cause of cancer death in young women worldwide — is radiotherapy and chemotherapy. However, the cancer’s resistance to chemotherapy and radiation, combined with a tendency to metastasis in the lymph nodes or recur in the pelvis, leaves doctors searching for more effective treatments.

Cervical cancer stem cells (CCSCs) are considered the major culprit behind the cancer’s ability to overcome these treatments. At the same time, a majority of cancer stem-like cells or tumor-initiating cells remain dormant. It takes a change in their microenvironment to spur them to metastasize.

“The mechanisms responsible for this must be identified to design more suitable therapies for the different subpopulations of cancer stem cells (CSCs) in various tissue-specific cancers,” said Hua Guo, Ph.D., who headed up the investigation along with Yuchao He, Ph.D. The two are colleagues at Tianjin Medical University Cancer Institute and Hospital. Researchers at Tianjin University of Traditional Chinese Medicine and at the Center for Translational Cancer Research, Peking University First Hospital, also participated in the study.

Although several cell surface antigens have been identified in CCSCs, these markers vary among tumors because of CSC heterogeneity. However, whether these markers specifically distinguish CCSCs with different functions is unclear. The study published in STEM CELLS sought to resolve this question. And in fact, its findings demonstrate that CCSCs exist in two biologically distinct phenotypes, characterized by different levels of cPLA2α expression.

“Our study showed for the first time that overexpression of cPLA2α results in a phenotype associated with mesenchymal traits, including increased invasive and migration abilities. On the other hand, CCSCs with cPLA2α downregulation show dormant epithelial characteristics,” said Dr. Guo. “In addition, cPLA2α regulates the reversible transition between mesenchymal and epithelial CCSC states through PKCζ, an atypical protein that governs cancer cell state changes.”

Dr. He added, “Now that we know cPLA2α triggers this transformation, we believe that cPLA2α might be an attractive therapeutic target for eradicating different states of CCSCs to eliminate tumors more effectively.”

“The novel study by Dr. Guo and team is of very high importance in understanding the transition between dormant cancer stem cells, which evade chemotherapy and radiation treatments, and actively dividing cells which can be better targeted, said Dr. Jan Nolta, Editor-in-Chief of STEM CELLS. “I applaud the group for this important discovery which will help researchers develop better treatments for cervical cancer.”

###

The full article, “cPLA2α reversibly regulate different subsets of cancer stem cells transformation in cervical cancer,” can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/stem.3157.

Figure Caption: This study revealed that there are two morphologically and functionally distinct cancer stem cell populations regulated by cPLA2α in cervical cancer. cPLA2α might be a unique marker to identify different cancer stem cell populations and trigger quiescent epithelial cancer stem cells transform to invasive mesenchymal states. Overexpression of cPLA2α resulted in a CD44+CD24- phenotype with mesenchymal traits, whereas cervical cancer stem cells (CCSCs) with cPLA2α downregulation expressed CD133 and showed epithelial characteristics. cPLA2α, as a key role to reversely regulate CCSCs states and EMT, might provide innovative therapeutic strategies intended to halt tumor recurrence and metastasis.

About the Journal: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. STEM CELLS is co-published by AlphaMed Press and Wiley.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS® (http://www.StemCells.com) is the world’s first journal devoted to this fast paced field of research. THE ONCOLOGIST® (http://www.TheOncologist.com) is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE® (http://www.StemCellsTM.com) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company’s website can be accessed at http://www.wiley.com.

Share article on social media or email:

Grain Foods Foundation Welcomes Siddhartha Angadi, PhD, FACSM, to Scientific Advisory Board


Siddhartha Angadi, PhD, FACSM

This is the perfect time to add Dr. Angadi’s expertise to the Foundation. We look forward to raising the visibility of the evidence-based dietary recommendations that result from his research among the nutrition community and the public.

The Grain Foods Foundation is excited to announce the addition of Siddhartha Angadi, PhD, FACSM, to its Scientific Advisory Board, effective February 1, 2020. A fellow of the American College of Sports Medicine, Dr. Angadi is currently an Assistant Professor at the College of Health Solutions at Arizona State University.

A cardiovascular exercise physiologist by training, Dr. Angadi’s research focuses on the complex interactions between exercise and physical activity, diet, and drugs in both healthy individuals and those with serious illnesses such as congestive heart failure, breast cancer, and end-stage renal disease.

“Given the rising prevalence of and deaths resulting from the illnesses that Dr. Angadi studies, this is the perfect time to add his expertise to the Foundation,” said Christine Cochran, executive director for the Grain Foods Foundation. “His research is impressive in both volume and breadth, and we look forward to raising the visibility of the evidence-based dietary recommendations that result from it among the nutrition community and the public.”

Dr. Angadi cites his most recent research – one Nutrients study that investigates the effects of glycemic index and dietary fiber on cardiovascular disease risk in adults, and another that examines the role of dietary fiber consumption on cardiovascular health in pediatric populations – as evidence that he clearly shares this ambition.

“I’m elated to join the Scientific Advisory Board,” Angadi said. “There’s a tremendous amount of misinformation out there when it comes to the role of diet in human health and disease, from one fad diet claiming that dietary fiber isn’t essential to another claiming that we’d all be better off without gluten. So I’m thrilled to partner with the Grain Foods Foundation and have the opportunity to help separate fact from fiction.”

Dr. Angadi joins the current members of the Scientific Advisory Board:

  • Glenn Gaesser, PhD (Chairman), Professor of Exercise Science and Health Promotion and Director of the Healthy Lifestyles Research Center at Arizona State University;
  • Dyan Hes, MD, owner and medical director of Gramercy Pediatrics in New York City;
  • Sylvia Melendez-Klinger, DBA, MS, RD, LDN, founder of Hispanic Food Communications;
  • Richard D. Mattes, MPH, PhD, RD, Distinguished Professor of Nutrition Science at Purdue University;
  • Julie Miller Jones, PhD, LN, CNS, Professor Emeritus at St. Catherine University;
  • Bruce Young, MD, Silverman Professor of Obstetrics and Gynecology at New York University School of Medicine;
  • Angela Ginn-Meadow, RD, LDN, CDE, Senior Education Coordinator at the University of Maryland’s Center for Diabetes and Endocrinology;
  • Pamela Cureton, RD, LDN, Division of Pediatric Gastroenterology and Nutrition at the University of Maryland School of Medicine;
  • Hannah Holscher, PhD, RD, Assistant Professor of Nutrition in the Department of Food Science and Human Nutrition at the University of Illinois.


About Grain Foods Foundation

Formed in 2004, Grain Foods Foundation (GFF) is a group of thought leaders and advocates for ALL grain foods and believes everybody needs grain food to enjoy a happy and healthy life. Committed to nutrition education programming that is firmly rooted in science, GFF is a strong advocate for our members, and a resource for consumers and the media who want to learn more about the role of grains in a well-balanced eating pattern. GFF offers research-based information and resources to members, partners, influencers, policymakers and consumers through a comprehensive communications campaign, conferences, webinars, research tools, social media and more. GFF is committed to bringing fact-based information and common sense to the consumer. For more information, visit grainfoodsfoundation.org.

Share article on social media or email:

Regen Suppliers is Now Offering FDA Cleared PDO Max Thread Lift Products


pdo max thread distributor

Now Offering PDO Max Threads (888) 568-6909

Regen Suppliers recognized that PDO Max products are not only first rate quality, but also available in fifteen different styles. The feedback we have received from providers is that they are better than any others on the market!

Regen Suppliers is now offering the top FDA Cleared threads available on the market, PDO Max. The first rate PDO thread lift products are not only one of the only FDA Cleared options available, there are fifteen different types in the portfolio.

Non invasive thread lift procedures are increasing exponentially in popularity, as they represent an excellent nonoperative method of reducing wrinkles and helping individuals look younger without the risks of an invasive surgery.

According to company VP Kathleen Francesca, “Regen Suppliers recognized that PDO Max products are not only first rate quality, but also available in fifteen different styles. The feedback we have received from providers is that they are better than any others on the market!”

PDO Max threads are available in several styles including Smuth (Smooth), Levo (Barbed) Threads, and Ciclone (Twisted) as well. The thread lift procedures are not only extremely popular for facial rejuvenation, but also being used for neck, knee, arm, abdomen and buttock lift procedures as well. The combination of smooth and barbed threads allow for sufficient new collagen and elastin formation for long lasting results.

In addition to offering all the styles of PDO Max threads, Regen Suppliers has teamed up with R3 Medical Training for its PDO Thread Lift Training Course. The Courses offer PDO Thread Lift Certification Training, as there is a steep learning curve to gain expertise. Many providers are now offering thread lift procedures in conjunction with regenerative biologics such as PRP, stem cells and exosomes. Regen Suppliers offers all of these biologics as well.

Those interested in PDO Thread Lift products should contact Regen Suppliers at (888) 568-6909.

Share article on social media or email: